INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION 5-Year Results of The Pan-American Collaborative Retina Study Group

Autor:	Arevalo JF, Lasave AF, Wu L, Acón D, Berrocal MH, Diaz-Llopis M, Gallego-Pinazo R, Serrano MA, Alezzandrini AA, Rojas S, Maia M, Lujan S
Rok vydání:	2016
Předmět:	genetic structures vascular endothelial growth factor aflibercept sense organs bevacizumab ranibizumab choroidal neovascularization eye diseases
Zdroj:	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname
ISSN:	0275-004X
Popis:	Purpose: To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB). Methods: Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits. Results: Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number of IVB injections per eye was 10.9 +/- 6.4. At 5 years, the BCVA decreased from 20/150 (logMAR 0.9 +/- 0.6) at baseline to 20/250 (logMAR 1.1 +/- 0.7) (P =
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2e4d264f56bba66c83fbbdd0e35810e3 https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=2256 Zobrazit plný text záznamu